### NEWS Calypte`s Urine HIV-1 Antibody Test - 500 Beiträge pro Seite
eröffnet am 19.09.02 13:06:03 von
neuester Beitrag 19.09.02 17:25:25 von
neuester Beitrag 19.09.02 17:25:25 von
Beiträge: 15
ID: 635.360
ID: 635.360
Aufrufe heute: 0
Gesamt: 491
Gesamt: 491
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
heute 20:01 | 5838 | |
vor 19 Minuten | 5528 | |
heute 20:28 | 5448 | |
heute 20:05 | 5104 | |
vor 19 Minuten | 4648 | |
vor 1 Stunde | 3380 | |
vor 52 Minuten | 3145 | |
heute 16:29 | 2691 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.500,48 | -0,12 | 120 | |||
2. | Neu! | 0,1800 | -83,67 | 74 | |||
3. | Neu! | 20,910 | -5,47 | 49 | |||
4. | 22. | 2.231,78 | +1,79 | 40 | |||
5. | Neu! | 0,9595 | +15,57 | 37 | |||
6. | 9. | 162,59 | -1,95 | 37 | |||
7. | 13. | 4,9230 | -0,47 | 36 | |||
8. | Neu! | 1,1450 | -6,93 | 35 |
PR NEWSWIRE) Calypte`s Urine HIV-1 Antibody Test Now Approved for Life Insur
Calypte`s Urine HIV-1 Antibody Test Now Approved for Life Insurance Screening
In All 50 States
West Virginia Department of Insurance Amends Rule to Include Urine HIV-1
Antibody Testing
ALAMEDA, Calif., Sept. 19 /PRNewswire-FirstCall/ --
Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and
marketer of the only two FDA-approved HIV-1 antibody tests that can be used on
urine samples, announced today that the West Virginia Office of the Insurance
Commissioner has cleared the way for urine HIV screening among life insurance
applicants in that state. With this decision, Calypte`s urine HIV-1 screening
test is now approved for use by the life insurance industry in all 50 states.
Until now, life and health insurance companies writing policies in West
Virginia have been unable to test specimens other than blood and oral fluid
for HIV. The Interpretive Rule amendment made by the commissioner is intended
to serve as a bridge to the effective date of the Legislative Rule, and allows
the urine-based screening to begin immediately. The Legislative Rule is
expected to be effective in the spring or summer of 2003.
"Life Insurance companies have been very receptive to urine-based testing
as an effective, convenient and cost-effective alternative to blood testing,"
said Nancy Katz, President and CEO of Calypte Biomedical. "We now have the
approval of approximately 150 insurance companies to order our tests,
including nine of the top 10 life insurance underwriters as ranked by policy
value. The Calypte urine antibody tests are completely non-invasive, which
results in a painless and comfortable way for insurance applicants to provide
a specimen. Also, urine testing is safe for those collecting the specimen who
otherwise would be at risk of contracting HIV from accidental needlestick
injuries. We are very pleased that the State of West Virginia has made
progress developing the necessary procedures that allow our life insurance
customers to expand their utilization of urine testing."
"Now that West Virginia has joined every other state in approving urine
screening tests for HIV-1 antibodies, we believe that it will be even easier
to get our message out to life insurance and other communities that our
proprietary urine screening test represents the future direction of HIV-1
screening," said Anthony Cataldo, Calypte`s Chairman.
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a
public healthcare company dedicated to the development and commercialization
of urine-based diagnostic products and services for Human Immunodeficiency
Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious
diseases. Calypte`s tests include the screening EIA and supplemental Western
Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on
urine samples. When compared with existing blood-based tests, our
testing algorithms are non-invasive, easier to use, less expensive and have
significantly less risk than blood-based testing, and they have 99.7%
sensitivity in subjects previously identified as HIV-1 infected and 100%
specificity in subjects at low risk when combined with the urine-based Western
Blot supplemental test. The company believes that accurate, non-invasive
urine-based testing methods for HIV and other infectious diseases may make
important contributions to public health by helping to foster an environment
in which testing may be done safely, economically, and painlessly. Calypte
markets its products in countries worldwide through international distributors
and strategic partners.
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Those statements include statements regarding the intent, belief
or current expectations of the Company and its management. Such statements
reflect management`s current views, are based on certain assumptions and
involve risks and uncertainties. Actual results, events, or performance may
differ materially from the above forward-looking statements due to a number of
important factors, and will be dependent upon a variety of factors, including,
but not limited to, our ability to obtain additional financing and access
funds from our existing financing arrangements that will allow us to continue
our current and future operations and whether demand for our product and
testing service in domestic and international markets will continue to expand.
The Company undertakes no obligation to publicly update these forward-looking
statements to reflect events or circumstances that occur after the date hereof
or to reflect any change in the Company`s expectations with regard to these
forward-looking statements or the occurrence of unanticipated events. Factors
that may impact the Company`s success are more fully disclosed in the
Company`s most recent public filings with the U.S. Securities and Exchange
Commission ("SEC"), including its annual report on Form 10-K for the year
ended December 31, 2001 and its subsequent filings with the SEC.
For further information, please contact Joe Bunning of Sitrick and
Company, +1-310-788-2850, for Calypte Biomedical Corporation.
SOURCE Calypte Biomedical Corporation
-0- 09/19/2002
/CONTACT: Joe Bunning of Sitrick and Company, +1-310-788-2850, for
Calypte Biomedical Corporation/
/Web site: http://www.calypte.com /
(CALY)
CO: Calypte Biomedical Corporation
ST: California, West Virginia
IN: MTC BIO HEA OTC INS
SU: LEG
*** end of story ***
Calypte`s Urine HIV-1 Antibody Test Now Approved for Life Insurance Screening
In All 50 States
West Virginia Department of Insurance Amends Rule to Include Urine HIV-1
Antibody Testing
ALAMEDA, Calif., Sept. 19 /PRNewswire-FirstCall/ --
Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and
marketer of the only two FDA-approved HIV-1 antibody tests that can be used on
urine samples, announced today that the West Virginia Office of the Insurance
Commissioner has cleared the way for urine HIV screening among life insurance
applicants in that state. With this decision, Calypte`s urine HIV-1 screening
test is now approved for use by the life insurance industry in all 50 states.
Until now, life and health insurance companies writing policies in West
Virginia have been unable to test specimens other than blood and oral fluid
for HIV. The Interpretive Rule amendment made by the commissioner is intended
to serve as a bridge to the effective date of the Legislative Rule, and allows
the urine-based screening to begin immediately. The Legislative Rule is
expected to be effective in the spring or summer of 2003.
"Life Insurance companies have been very receptive to urine-based testing
as an effective, convenient and cost-effective alternative to blood testing,"
said Nancy Katz, President and CEO of Calypte Biomedical. "We now have the
approval of approximately 150 insurance companies to order our tests,
including nine of the top 10 life insurance underwriters as ranked by policy
value. The Calypte urine antibody tests are completely non-invasive, which
results in a painless and comfortable way for insurance applicants to provide
a specimen. Also, urine testing is safe for those collecting the specimen who
otherwise would be at risk of contracting HIV from accidental needlestick
injuries. We are very pleased that the State of West Virginia has made
progress developing the necessary procedures that allow our life insurance
customers to expand their utilization of urine testing."
"Now that West Virginia has joined every other state in approving urine
screening tests for HIV-1 antibodies, we believe that it will be even easier
to get our message out to life insurance and other communities that our
proprietary urine screening test represents the future direction of HIV-1
screening," said Anthony Cataldo, Calypte`s Chairman.
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a
public healthcare company dedicated to the development and commercialization
of urine-based diagnostic products and services for Human Immunodeficiency
Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious
diseases. Calypte`s tests include the screening EIA and supplemental Western
Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on
urine samples. When compared with existing blood-based tests, our
testing algorithms are non-invasive, easier to use, less expensive and have
significantly less risk than blood-based testing, and they have 99.7%
sensitivity in subjects previously identified as HIV-1 infected and 100%
specificity in subjects at low risk when combined with the urine-based Western
Blot supplemental test. The company believes that accurate, non-invasive
urine-based testing methods for HIV and other infectious diseases may make
important contributions to public health by helping to foster an environment
in which testing may be done safely, economically, and painlessly. Calypte
markets its products in countries worldwide through international distributors
and strategic partners.
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Those statements include statements regarding the intent, belief
or current expectations of the Company and its management. Such statements
reflect management`s current views, are based on certain assumptions and
involve risks and uncertainties. Actual results, events, or performance may
differ materially from the above forward-looking statements due to a number of
important factors, and will be dependent upon a variety of factors, including,
but not limited to, our ability to obtain additional financing and access
funds from our existing financing arrangements that will allow us to continue
our current and future operations and whether demand for our product and
testing service in domestic and international markets will continue to expand.
The Company undertakes no obligation to publicly update these forward-looking
statements to reflect events or circumstances that occur after the date hereof
or to reflect any change in the Company`s expectations with regard to these
forward-looking statements or the occurrence of unanticipated events. Factors
that may impact the Company`s success are more fully disclosed in the
Company`s most recent public filings with the U.S. Securities and Exchange
Commission ("SEC"), including its annual report on Form 10-K for the year
ended December 31, 2001 and its subsequent filings with the SEC.
For further information, please contact Joe Bunning of Sitrick and
Company, +1-310-788-2850, for Calypte Biomedical Corporation.
SOURCE Calypte Biomedical Corporation
-0- 09/19/2002
/CONTACT: Joe Bunning of Sitrick and Company, +1-310-788-2850, for
Calypte Biomedical Corporation/
/Web site: http://www.calypte.com /
(CALY)
CO: Calypte Biomedical Corporation
ST: California, West Virginia
IN: MTC BIO HEA OTC INS
SU: LEG
*** end of story ***
Ihr wisst was zu tun ist wenn der Kurs heute weiter absackt!
morchel
morchel
@ morchel
so? was denn?
zur meldung:
49+1=welch horrende umsatzsteigerungen das jetzt wohl bringen mag...
ich tippe mal: spätestens zum WE .071
so? was denn?
zur meldung:
49+1=welch horrende umsatzsteigerungen das jetzt wohl bringen mag...
ich tippe mal: spätestens zum WE .071
Hallo Leute!
Habe mich schon gewundert warum der Kurs in Frankfurt von 8 auf 10 Cent wieder gestiegen ist. Wenn ihr mir den Beitrag oben in kleien Sätzen übersetzt kann ich mich mit freuen.
Danke!!!!!
Habe mich schon gewundert warum der Kurs in Frankfurt von 8 auf 10 Cent wieder gestiegen ist. Wenn ihr mir den Beitrag oben in kleien Sätzen übersetzt kann ich mich mit freuen.
Danke!!!!!
#4
der test wurde nun auch im 50. us-bundesstaat zugelassen.
gab es für die anderen 49 auch jeweils eine eigene PR? würde mich nicht wundern...
der test wurde nun auch im 50. us-bundesstaat zugelassen.
gab es für die anderen 49 auch jeweils eine eigene PR? würde mich nicht wundern...
und was heisst das jetzt?
#6
außer potentiellem umsatzwachstum von 1 oder 2 prozent? nichts.
außer potentiellem umsatzwachstum von 1 oder 2 prozent? nichts.
09/19/2002 (08:40 ET) The Subway.com Covers CALY - Knobias
09/19/2002 (08:28 ET) TheSubway.com: TheSUBWAY.com announces Stock Focus List -- Potential market movers! - M2 Communications
09/19/2002 (08:23 ET) TheSUBWAY.com Posts Investment Opinion: Today`s Market Picks! - Business Wire
09/19/2002 (07:00 ET) Calypte`s Urine HIV-1 Antibody Test Now Approved for Life Insurance Screening In All 50 States - PR Newswire
09/18/2002 (08:05 ET) New 424B3 just released for CALY - Edgar
JS200
09/19/2002 (08:28 ET) TheSubway.com: TheSUBWAY.com announces Stock Focus List -- Potential market movers! - M2 Communications
09/19/2002 (08:23 ET) TheSUBWAY.com Posts Investment Opinion: Today`s Market Picks! - Business Wire
09/19/2002 (07:00 ET) Calypte`s Urine HIV-1 Antibody Test Now Approved for Life Insurance Screening In All 50 States - PR Newswire
09/18/2002 (08:05 ET) New 424B3 just released for CALY - Edgar
JS200
naja +20% für "nichts" ist doch ok.
naja, 20% für "was" wären mir da doch lieber.
20% = 20%
nichts=nichts
"nichts" = 26%
Wenn das so weiter geht könen auch nichts=50% werden!!!
Oder wie seht ihr das?
Bin auch schon seit über 1 Jahr in Caly investiert, auch noch mit Miesen - bin aber optimistisch Caly wird ein Riesenkracher werden!!! Geduld zahlt sich aus.
See soon
Oder wie seht ihr das?
Bin auch schon seit über 1 Jahr in Caly investiert, auch noch mit Miesen - bin aber optimistisch Caly wird ein Riesenkracher werden!!! Geduld zahlt sich aus.
See soon
.... leute, leute, leute ....
schaut mal auf die volumina in den usa - unglaublich!!! - liegt schon bei über 300000 nach gerade mal eineinhalb stunden handel....bei einem solchen wert sehr sehr ordentlich ...
... da geht noch was ...
schaut mal auf die volumina in den usa - unglaublich!!! - liegt schon bei über 300000 nach gerade mal eineinhalb stunden handel....bei einem solchen wert sehr sehr ordentlich ...
... da geht noch was ...
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
120 | ||
74 | ||
49 | ||
40 | ||
37 | ||
37 | ||
36 | ||
35 | ||
34 | ||
32 |
Wertpapier | Beiträge | |
---|---|---|
31 | ||
31 | ||
31 | ||
30 | ||
29 | ||
26 | ||
26 | ||
25 | ||
24 | ||
23 |